High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation
Top Cited Papers
- 27 October 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 88 (8), 1019-1024
- https://doi.org/10.1097/tp.0b013e3181b9d710
Abstract
Background. Although donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) have been implicated in graft rejection in solid organ transplantation, their role in hematopoietic stem-cell transplantation remains unclear. Methods. To address the hypothesis that the presence of DSA contributes to the development graft failure, we tested 24 consecutive patients for the presence of anti-HLA antibodies determined by a sensitive and specific solid-phase/single-antigen assay. The study included a total of 28 haploidentical transplants, each with 2 to 5 HLA allele mismatches, at a single institution, from September 2005 to August 2008. Results. DSA were detected in five patients (21%). Three of four (75%) patients with DSA before the first transplant failed to engraft, compared with 1 of 20 (5%) without DSA (P=0.008). All four patients who experienced primary graft failure had second haploidentical transplants. One patient developed a second graft failure with persistent high DSA levels, whereas three engrafted, two of them in the absence of DSA. No other known factors that could negatively influence engraftment were associated with the development of graft failure in these patients. Conclusions. These results suggest that donor-specific anti-HLA antibodies are associated with a high rate of graft rejection in patients undergoing haploidentical stem-cell transplantation. Anti-HLA sensitization should be evaluated routinely in hematopoietic stem-cell transplantation with HLA mismatched donors.Keywords
This publication has 30 references indexed in Scilit:
- A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantationBlood, 2008
- Allogeneic Hematopoietic Stem Cell Transplant Using Mismatched/Haploidentical DonorsTransplantation and Cellular Therapy, 2007
- Hematopoietic Stem-Cell TransplantationNew England Journal of Medicine, 2006
- Long-term outcome after haploidentical stem cell transplantation in childrenBlood Cells, Molecules, and Diseases, 2004
- Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA HaplotypeNew England Journal of Medicine, 1998
- Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated miceNature Medicine, 1995
- Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor ProgramNew England Journal of Medicine, 1993
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- LONG-TERM REMISSIONS IN ACUTE MYELOGENOUS LEUKAEMIAThe Lancet, 1984
- Significance of the Positive Crossmatch Test in Kidney TransplantationNew England Journal of Medicine, 1969